



ASX & Media Release

## Patrys Provides Update on CEO Position

**Melbourne, Australia; 29 October, 2014:** Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company provides an update on the status of its transition planning following the resignation of Dr. Marie Roskrow as Managing Director and CEO last month.

In order to facilitate a smooth transition to the existing management team it has been determined that Dr. Roskrow will retire from the Company with immediate effect. Mr. Roger McPherson (CFO and Company Secretary) has been appointed as interim CEO pending the appointment of a permanent replacement CEO.

Mr. John Read, Chairman of Patrys said: “The Board has decided that at this important time in the Company’s development the entire Patrys team should be involved in the Company’s future development. We would like to thank Roger, who has been with the Company for 6 years and as such is across all ongoing activities, for agreeing to step up into the role of CEO on an interim basis. Roger will lead the Patrys teams in Melbourne and Würzburg at this exciting time for the Company as we move towards our next clinical trial. The Board is also actively screening potential permanent CEO candidates and hopes to be in a position to make an announcement in this regard in the short term. We would again like to thank Marie for her contribution to the Company.”

**-Ends-**

**For further information, please contact:**

Patrys Limited:  
Roger McPherson  
Interim CEO  
P: +61 3 96703273  
[info@patrys.com](mailto:info@patrys.com)

Patrys IR:  
Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

Patrys Media:  
Kellie Hanrick  
Buchan Consulting  
P: +61 3 9866 4722  
[khanrick@buchanwe.com.au](mailto:khanrick@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com)